

**Table S1** Summary of target treatment lines

Target therapy	All (N=143)
Patients with first line target therapy only	103
Pazopanib	103 (72.0%)
Treatment ongoing	
No	37 (35.9%)
Yes	66 (64.1%)
Patients switch to second line target therapy	34
Pazopanib/axitinib	24 (16.8%)
Pazopanib/everolimus	6 (4.2%)
Pazopanib/sorafenib	3 (2.1%)
Pazopanib/sunitinib	1 (0.7%)
Patients switch to third line target therapy	6
Pazopanib/axitinib/axitinib	1 (0.7%)
Pazopanib/axitinib/everolimus	1 (0.7%)
Pazopanib/axitinib/sunitinib	1 (0.7%)
Pazopanib/everolimus/axitinib	1 (0.7%)
Pazopanib/everolimus/cabozatinib	1 (0.7%)
Pazopanib/sunitinib/axitinib	1 (0.7%)